Engineered toxins "zymoxins" are activated by the HCV NS3 protease by removal of an inhibitory protein domain.
The synthesis of inactive enzyme precursors, also known as "zymogens," serves as a mechanism for regulating the execution of selected catalytic activities in a desirable time and/or site. Zymogens are usually activated by proteolytic cleavage. Many viruses encode proteases that execute key...
Guardado en:
Autores principales: | Assaf Shapira, Meital Gal-Tanamy, Limor Nahary, Dana Litvak-Greenfeld, Romy Zemel, Ran Tur-Kaspa, Itai Benhar |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/52f1c18b1d9a4efdb713441d923e9515 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Removal of hepatitis C virus-infected cells by a zymogenized bacterial toxin.
por: Assaf Shapira, et al.
Publicado: (2012) -
Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors
por: Ashley N. Matthew, et al.
Publicado: (2020) -
Structure of the NS2B-NS3 protease from Zika virus after self-cleavage
por: Wint Wint Phoo, et al.
Publicado: (2016) -
Effects of Lower Temperature on Expression and Biochemical Characteristics of HCV NS3 Antigen Recombinant Protein
por: Chen-Ji Huang, et al.
Publicado: (2021) -
First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients
por: Zahra Hasanshahi, et al.
Publicado: (2021)